AELIS Share Price Performance
€1.15
-0.83 (-41.92%)
Price €1.15
Share Pricen/a
Aelis Farma SA Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 8 Fair Values set on narratives written by author
AELIS Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Aelis Farma SA Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -0.60
- 100.00%
- -351.31%
- 96.3%
About AELIS
- Founded
- 2013
- Employees
- 24
- CEO
- WebsiteView website
Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase II clinical trials to treat cognitive deficits observed in down syndrome, as well as other cognitive impairments. Aelis Farma SA was incorporated in 2013 and is headquartered in Bordeaux, France.
